Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer

doi:10.4240/wjgs.v16.i10.3224

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (754)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-4) series.

Item

Count

PDF

HTML

381

Figures (1-7)

Tables (1-4)

Sum=477

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

110

Download

140

Sum=250

Publishing Process of This Article

Item

Count

Browse

Download

Sum=17

Oct 27, 2024 (publication date) through Oct 19, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Oct 27, 2024; 16(10): 3224-3238
Published online Oct 27, 2024. doi: 10.4240/wjgs.v16.i10.3224

Full Size Figure Download Figure

Figure 1 Comparison of overall survival and progression-free survival between the two groups. A: Overall survival; B: Progression-free survival. P-SOX: Nab-paclitaxel and oxaliplatin + S-1; SOX: Standard S-1 and oxaliplatin; HR: Hazard ratio; PFS: Progression-free survival; OS: Overall survival.

Citation: Wang YC, Feng L, Wang GP, Yu PJ, Guo C, Cai BJ, Song Y, Pan T, Lin BH, Li YD, Xiao JJ. Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer. World J Gastrointest Surg 2024; 16(10): 3224-3238
URL: https://www.wjgnet.com/1948-9366/full/v16/i10/3224.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i10.3224